Payment overview · 2025
General Payments
$21,032.88
50 reported records · 11 companies
Healthcare provider profile · identity verified
Tulio Bertorini, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · MEMPHIS, TN · NPI 1760459168
Verified facts
What the public records show
CMS Open Payments records show Tulio Bertorini, MD received $21,032.88 in general payments during 2025 across 50 reported records.
ARGENX US, INC. accounted for 41.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
Alexion Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIRIS as an associated drug or biological on 303 records involving 233 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Soliris by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SKYCLARYS as an associated drug or biological on 3512 records involving 2165 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Skyclarys by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $8,618.97 | 41.0% | 14 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $7,191.21 | 34.2% | 8 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $4,719.79 | 22.4% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $224.63 | 1.1% | 14 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $130.60 | 0.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $55.69 | 0.3% | 3 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $23.22 | 0.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.69 | 0.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.15 | 0.1% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $15.89 | 0.1% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.04 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $19,010.00 | 10 |
| Consulting Fee | $1,040.00 | 1 |
| Food and Beverage | $918.36 | 32 |
| Travel and Lodging | $64.52 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $7,931.98 | 10 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $7,191.21 | 8 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $4,719.79 | 5 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $209.50 | 10 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $134.62 | 7 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $61.99 | 3 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $55.69 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.69 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $19.69 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| QALSODY Normalized: qalsody |
Drug | Biogen, Inc. | $15.89 | 1 | 2025 |
Source payment records
|
|||||
| SPINRAZA Normalized: spinraza |
Biological | Biogen, Inc. | $15.89 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.13 | 4 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $15.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Alexion Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SOLIRIS open payments reported associated product |
CMS Open Payments — General Payments 303 supporting records · 233 recipient NPIs · example record 1202913090 |
Soliris · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | SKYCLARYS open payments reported associated product |
CMS Open Payments — General Payments 3512 supporting records · 2165 recipient NPIs · example record 1208299709 |
Skyclarys · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 352 | 72 |
| Radicava Ors | Edaravone | 243 | 32 |
| Prednisone | Prednisone | 218 | 44 |
| Baclofen | Baclofen | 208 | 41 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 179 | 46 |
| Riluzole | Riluzole | 151 | 30 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 120 | 27 |
| Sodium Chloride | 0.9 % Sodium Chloride | 115 | 20 |
| Azathioprine | Azathioprine | 109 | 28 |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 88 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 77 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 72 | 23 |
| Pregabalin | Pregabalin | 70 | 20 |
| Gammaked | Immune Globul G/Gly/Iga Avg 46 | 69 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 62 | 18 |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 59 | suppressed |
| Clonazepam | Clonazepam | 55 | suppressed |
| Folic Acid | Folic Acid | 45 | suppressed |
| Levetiracetam | Levetiracetam | 44 | 11 |
| Octagam | Immun Globg(Igg)/Malt/Iga Ov50 | 41 | suppressed |
| Methotrexate | Methotrexate Sodium | 40 | 14 |
| Alprazolam | Alprazolam | 39 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Memantine Hcl | Memantine Hcl | 35 | suppressed |
| Primidone | Primidone | 35 | suppressed |
| Relyvrio | Sod Phenylbutyrat/Taurursodiol | 32 | 16 |
| Soliris | Eculizumab | 32 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 31 | suppressed |
| Carbamazepine | Carbamazepine | 30 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 28 | suppressed |
| Dalfampridine Er | Dalfampridine | 27 | suppressed |
| Gammaplex | Immun Glob G(Igg)/Gly/Iga 0-50 | 27 | suppressed |
| Mexiletine Hcl | Mexiletine Hcl | 27 | suppressed |
| Hizentra | Immun Glob G(Igg)/Pro/Iga 0-50 | 26 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 25 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 24 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 23 | suppressed |
| Diazepam | Diazepam | 23 | suppressed |
| Phenobarbital | Phenobarbital | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 19 | suppressed |
| Amantadine | Amantadine Hcl | 18 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 15 | suppressed |
| Lacosamide | Lacosamide | 15 | suppressed |
| Scopolamine | Scopolamine | 15 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 13 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 13 | suppressed |
| Evrysdi | Risdiplam | 13 | suppressed |
| Famotidine | Famotidine | 13 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 13 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 13 | suppressed |
| Rytary | Carbidopa/Levodopa | 13 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 12 | suppressed |
| Meloxicam | Meloxicam | 12 | suppressed |
| Neupro | Rotigotine | 12 | suppressed |
| Omeprazole | Omeprazole | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Phenytoin | Phenytoin | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Skyclarys | Omaveloxolone | 12 | suppressed |
| Topiramate Er | Topiramate | 12 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $21,032.88 · 50 records | ARGENX US, INC. | AMVUTTRA, BOTOX, KISUNLA, NURTEC ODT, QALSODY, QULIPTA, Rystiggo, SPINRAZA, UBRELVY, ULTOMIRIS, UPLIZNA, VYVGART, VYVGART HYTRULO, ZAVZPRET | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Alexion Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error